The presence of a deletion or mutation of the TP53 gene in CLL is known to be associated with an unsatisfactory treatment outcome, rapid disease progression, and insensitivity to therapy [11]. The gene discussed is TP53; the disease is B-cell chronic lymphocytic leukemia.